Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: Apixaban vs Aspirin in ICH Survivors with AF
NCT03907046Phase 3Recruiting
- Sponsor
- Yale University
- Start
- Jan 2020
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apixaban in stroke and Atrial fibrillation (AFib) (2 arms), sponsored by Yale University. Primary endpoint: Composite of any stroke (hemorrhagic or ischemic) or death from any cause at 3 years. Started Jan 2020; status: recruiting.
02
Drugs
apixaban
03
Conditions
strokeAtrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03907046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907046.